Sun Pharma shares in focus after muted Q2 earnings. Nuvama maintains hold with Rs 1,800 target
[hfe_template id='11223']
[ad_1]
Shares of Sun Pharmaceutical Industries will be in focus heading into trade on Thursday, November 6, after the company reported a net profit after tax of Rs 3,117.95 crore for Q2 FY26, a 2.6% year-on-year (YoY) increase compared to Rs 3,040.16 crore in the year-ago period. Revenue from operations for the quarter ended September 2025 stood at Rs 14,405.22 crore, up 8.6% YoY from Rs 13,264.22 crore reported in the September 2024 quarter. Sun Pharma posted EBITDA of Rs 4,527.1 crore, a 14.9% YoY rise, with an EBITDA margin of 31.3%. Profit before exceptional items and tax increased 15.8% to Rs 4,167.6 crore. Sales from the Global Innovative Medicines segment were $333 million, up 16.4% YoY, accounting for 20.2% of total revenue. The company said U.S. sales of Innovative Medicines surpassed Generics for the first time during the quarter. Research and development investment stood at Rs 782.7 crore, or 5.4% of sales. Live Events Kirti Ganorkar,...